# Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer

> **NCT05764941** · — · UNKNOWN · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 100 (estimated)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Inetetamab
- **DRUG:** Pyrotinib
- **DRUG:** Vinorelbine

## Key facts

- **NCT ID:** NCT05764941
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-01
- **Primary completion:** 2024-03-01
- **Final completion:** 2024-03-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2023-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05764941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05764941, "Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05764941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*